Strategic Partnerships Scailyte collaborates with clinical-stage biotech and pharma globally and has a large network of clinical partners, presenting immediate opportunities for biomarker-driven drug development collaborations and multi-omics platform services.

AI Platform Advantage Leveraging the ScaiVision AI platform and 60 million single-cell profiles, Scailyte can offer advanced biomarker discovery, predictive signatures, and expansion into multi-omics data integration for partner programs.

Funding Momentum Recent Innosuisse grants and a notable CHF 800k award indicate government-backed validation and available non-dilutive funding for collaborative R&D projects, which can co-finance partner-led initiatives.

Expansion & Leadership Strategic leadership moves including the addition of a Chief Business Officer and active conference presence signal growing sales capability and outbound outreach opportunities to scale partnerships.

Market Position As an ETH Zurich spin-off with a focus on oncology and auto-immunity, Scailyte presents a compelling value proposition for biopharma seeking precision medicine biomarkers, enabling targeted asset optimization and faster go/no-go decisions.